SuchitraSAcharyaMD
Oncology • New Hyde Park, NYProfessor, Pediatrics, Hofstra Northwell School of Medicine; Director Hemostasis and Thrombosis Center, Northwell Health
Dr. Acharya is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
269-01 76th Ave
Suite 255
New Hyde Park, NY 11040Phone+1 718-470-3460Fax+1 718-343-4642
Summary
- Dr. Suchitra Acharya is an oncology specialist based in New Hyde Park, NY, with a focus on pediatric hematology/oncology, hematologic oncology, thrombotic disorders, and bleeding disorders. She completed her residency in pediatrics at Westchester Medical Center and her fellowship in pediatric hematology/oncology at New York Presbyterian Hospital (Cornell Campus). She graduated from Seth G.S. Medical College in 1985. Dr. Acharya has contributed to several publications, including research on hemophilia and inherited disorders of the fibrinolytic pathway. She has been involved in clinical trials such as SEVENFACT® for bleeding events in hemophilia, the evaluation of therapy duration for thrombosis in children, and the use of ultrasound in diagnosing hemophilic joint disease.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1996 - 1999
Westchester Medical CenterResidency, Pediatrics, 1993 - 1995
Seth G.S. Medical CollegeClass of 1985
Certifications & Licensure
NY State Medical License 1996 - 2026
CT State Medical License 2006 - 2007
NJ State Medical License 2007 - 2007
American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Study to Evaluate the Use of Ultrasound in the Diagnosis of Hemophilic Joint Disease Start of enrollment: 2005 Sep 01
- Evaluation of the Duration of Therapy for Thrombosis in Children Start of enrollment: 2008 Mar 01
- SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors Start of enrollment: 2021 Jun 28
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 1 citationsSecondary Anticoagulation Use in Patients < 21 Years Old following Primary Anticoagulant Treatment for Provoked Venous Thromboembolism: Findings from the Kids-DOTT Trial.Hope P Wilson, Maua Mosha, Alexandra Miller, Marisol Betensky, Ernest Amankwah
Seminars in Thrombosis and Hemostasis. 2025-04-01 - Bone Health Screening in Persons With Bleeding Disorders: A Survey of United States Haemophilia Treatment Centres.Divyaswathi Citla-Sridhar, Sanjay Ahuja, Robert Sidonio, Meera Chitlur, Anjali Sharathkumar
Haemophilia. 2025-03-07 - 3 citationsInherited Disorders of the Fibrinolytic Pathway: Pathogenic Phenotypes and Diagnostic Considerations of Extremely Rare Disorders.Maha Al-Ghafry, Mouhamed Yazan Abou-Ismail, Suchitra S Acharya
Seminars in Thrombosis and Hemostasis. 2025-03-01
Abstracts/Posters
- Assessment of Provider Practices Regarding Management of VTE in Pediatric LeukemiaSuchitra Acharya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Provider Practices Regarding Prophylactic Anticoagulation in Children with LeukemiaSuchitra Acharya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Marstacimab Gets FDA Nod for Hemophilia a or B Without InhibitorsOctober 11th, 2024- FDA Approves First Once-Weekly Drug Treatment Regimen for HemophiliaOctober 11th, 2024
- U.S. FDA Approves Pfizer’s HYMPAVZI™ (Marstacimab-Hncq) for the Treatment of Adults and Adolescents with Hemophilia a or B Without InhibitorsOctober 11th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
